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Abstract: 
Conformationally constrained peptidomimetics may be of great value in the design of 
vaccines targeting protective epitopes on viral and bacterial pathogens. But the poor 
immunogenicity of small synthetic molecules represents a serious obstacle for their use in 
vaccine development. Here, we show how a constrained epitope mimetic can be rendered 
highly immunogenic through multi-valent display on the surface of synthetic virus-like 
nanoparticles. The target epitope is the V3 loop from the gp120 glycoprotein of HIV-1 bound 
to the neutralizing antibody F425-B4e8. The antibody-bound V3 loop adopts a ß-hairpin 
conformation, which is effectively stabilized by transplanting onto a D-Pro-L-Pro template. 
The resulting mimetic after coupling to synthetic virus-like particles elicited antibodies in 
rabbits that recognized recombinant gp120. The elicited antibodies also blocked infection by 
the neutralization sensitive tier-1 strain MN of HIV-1, as well as engineered viruses with the 
V1V2 loop deleted, a result consistent with screening of V3 by the V1V2 loop in intact 
trimeric viral gp120 spikes. The results provide new insights into HIV-1 vaccine design 
based on the V3 loop, and illustrate how knowledge from structural biology can be exploited 
for the design of constrained epitope mimetics, which can be delivered to the immune system 
using a highly immunogenic synthetic nanoparticle delivery system. 
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Introduction 
Preventive vaccine design has traditionally been approached empirically through 
immunizations with dead or attenuated microorganisms to induce protective immunity.[1] 
Considering the complexity of such vaccine preparations, it is not suprising that little is 
understood at a molecular level about their pharmacology and detailed mechanism(s) of 
action in the host.[2] More recently, the focus in vaccine design has shifted to subunit 
vaccines, where protein subunits are used to generate a protective immune response. Reverse 
vaccinology approaches can exploit advances in microbial genomics and proteomics to 
enable high-throughput production and testing of recombinant microbial proteins, in order to 
identify potential protein-based vaccine candidates.[3] Difficulties arise, however, because 
recombinant proteins tend to be poorly immunogenic, and so they are typically administered 
together with immunostimulatory adjuvants.[4] Moreover, the reactogenicity of some of the 
most potent preclinical adjuvants and the cost and complexity of licensing new adjuvants for 
human use remains a serious problem.[4, 5] Recombinant proteins may also be incorrectly 
folded, and may expose irrelevant epitopes that are normally hidden on the pathogen surface, 
leading generally to poorly protective immune responses. The use of peptides to focus 
immune responses on protective surface epitopes has also attracted great interest.[6] However, 
linear peptides are flexible and so often do not mimic well conformational protein epitopes, 
they tend to have an unfavorable pharmacology in-vivo due to proteolysis, and their ability to 
induce humoral immune responses (immunogenicity) is again very poor. These factors may 
explain why no peptide-based vaccine has so far been developed for human use. 
 Most preventive vaccines are based on the induction of neutralizing antibodies in the 
host, which recognize protective epitopes on the surfaces of bacteria or viruses. The 
mechanisms by which the immune system is activated are now becoming increasingly well 
understood at the molecular and cellular levels. Important signals for the activation of 
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immune cells are provided by; 1) repetitive multi-valent display of B-cell epitopes across a 
bacterial or viral surface, to cross-link cell-surface B-cell receptors and stimulate B-cell 
activation[7, 8]; 2) peptide fragments comprising T-cell epitopes derived from pathogen 
proteins produced inside antigen presenting cells (e.g. dendritic cells), are displayed in 
complexes with MHC-I and -II proteins on the cell surface, where they are recognized by T-
cell receptors on T-cells.[9] Activated T-cells then provide crucial help to B-cells during the 
maturation phase of the adaptive immune response; 3) dendritic cells (DCs) are the sentinel 
cells in the body that can sense invading microorganisms and alert other cells of the immune 
system.[10] Their cell surface receptors allow efficient uptake and internalization of soluble or 
particulate matter in the periphery, leading to proteolytic processing of internalized protein 
antigens and MHC presentation of peptide fragments. After migration to and entry into the 
lymph nodes, surface bound antigens on dendritic cells are screened by B-cells,[11] whereas 
peptide-MHC complexes on the cell surface are screened by T-cells. In addition, already in 
the periphal tissues DCs become activated, by sensing microbial products using innate 
immunity receptors such as those belonging to the Toll-like Receptor (TLR) family.[12, 13] 
This leads to up-regulation of MHC expression, production of immunostimulatory cytokines, 
and enhanced migration to the lymph nodes. Knowledge of these mechanisms of immune 
activation at a molecular level opens new possibilities for vaccine design, using rational 
structure-based methods. 
 In earlier work, we reported the design of synthetic lipopeptide conjugates that have 
the ability to spontaneously self-assemble in aqueous solution into small and remarkably 
homogeneous virus-sized nanoparticles of ca. 20-30 nm diameter, called synthetic virus-like 
particles (SVLPs).[14-16] The design of the lipopeptides is guided by knowledge that some 
lipopeptides of bacterial origin containing Pam2Cys or Pam3Cys, are TLR ligands.[17, 18] T-
cell epitopes can also be incorporated into the peptide portion of the lipopeptide, and B-cell 
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epitopes can be added such that after SVLP formation, multiple copies of the epitope are 
displayed over the particle surface. Hence, some of the key immunostimulatory signals 
required for immune activation are present in a nanoparticle, which can be produced from a 
synthetically-derived molecule. We have shown that SVLPs can be used to elicit strong 
humoral immune responses in animal models without the use of adjuvants, including in one 
example, antibodies that could recognize a natural epitope on the malaria parasite.[16] We are 
interested to explore whether this delivery system can be further developed for vaccine use. 
Here we describe efforts to display conformationally constrained peptidomimetics on the 
surface of SVLPs, which offers the prospect of using knowledge from structural biology for 
epitope mimetic design. As a target antigen we chose the V3 loop in the gp120 envelope 
glycoprotein from HIV-1. We describe a highly effective method for producing accurate 
constrained mimics of this epitope, and show that the mimics can be used to elicit antibodies 
that neutralize infection by some strains of HIV-1. 
 HIV-1 entry into cells begins with binding of viral surface envelope glycoprotein 
trimers composed of non-covalently linked gp41 and gp120 subunits, to the cellular receptor 
CD4 on host cells.[19] This interaction triggers conformational changes within gp120 that 
increase exposure of the third variable region (V3) loop and a region of gp120 between the 
inner and outer domains that interacts with the co-receptor, either CCR5 or CXCR4.[20] This 
allows V3 to dock with the co-receptor extracellular surface, thereby stabilizing the 
complex.[21, 22]  
 The V3 region is typically a 35 amino acid, hypervariable, glycosylated and disulfide-
bonded hairpin loop, with a highly conserved motif (GPGR/Q; residues 312-315 in the HXB2 
numbering scheme[23]) in a ß-turn at the tip (Figure-1). A crystal structure of an engineered 
gp120 from strain JR-FL bound to CD4 and a neutralizing antibody (X5) Fab fragment (PDB 
2B4C) revealed for the first time the intact V3 loop in an extended ß-hairpin conformation.[24] 
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Another crystal structure of an engineered gp120-CD4 complex bound to a tyrosine-sulfated 
antibody Fab (412d) (PDB 2QAD) revealed a more rigid V3 loop in a different ß-hairpin 
conformation, with the incoming and outgoing strands of the V3 stem closer together and the 
ß-hairpin structure again capped by a ß-turn (Figure-1).[21] In addition, a large number of 
crystal structures are available of various V3 loop-derived peptides bound to different 
neutralizing antibody Fab fragments, which reveal the V3 peptide in various ß-hairpin 
conformations.[25-29]  
 For this work, we started from a crystal structure of a V3 loop-derived peptide 
(sequence shown in Figure-1) bound to the human mAb F425-B4e8 (see Figure-2).[30] This 
antibody is able to neutralize cellular infection by a number of different HIV-1 strains, and so 
is an interesting target for the design of a vaccine able to elicit F425-B4e8-like antibodies.[31] 
 
 
Results 
Design of V3 loop mimetics 
The crystal structure of a V3 loop-derived linear peptide bound to the antibody F425-B4e8 is 
shown in Figure-2. The V3 loop adopts a ß-hairpin conformation, with cross-strand residue 
pairs I307/Y318, and K305/T320 at hydrogen-bonding (HB) positions. The dipeptide D-Pro-
L-Pro can be used as a template to stabilize hairpin conformations and to fix the hairpin 
register in macrocyclic hairpin mimetics.[32] The pair of residues directly attached to the 
template should orient their side chains onto the same face of the hairpin, and occupy a HB 
position adjacent to the template. In the ß-hairpin mimetic shown in Figure-2, the HB pair 
K305/T320 are directly attached to the template. The mimetic was synthesized by standard 
methods and purified by HPLC (see Supporting Information).[33] 
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Conformational studies 
The structure of the mimetic in aqueous solution (H2O/D2O, pH 5.0) was investigated by 
NMR spectroscopy. Major and minor conformers were detected in solution that interconvert 
slowly, due to cis-trans isomerization (1:3 ratio) at the Gly-Pro peptide bond at the tip of the 
hairpin. Structural studies were pursued with the trans-form, which is present in excess (see 
Figure-3). 
 The 3JHNα values were mostly >8Hz for residues expected to lie in ß-strands, 
consistent with the proposed ß-hairpin conformations.[34] All amide NH protons exchanged 
rapidly with solvent (within the time taken to measure a spectrum), and so were not helpful 
for identifying cross-strand hydrogen-bonded amide groups. However, the ΔδNH/ΔT 
temperature coefficients of residues predicted to occupy HB positions in ß-strands are lower 
(more positive than -4.5 ppb/K) than those for residues in NHB positions. In proteins, a 
temperature coefficient more positive than -4.5 ppb/k indicates a likely hydrogen bonded 
NH.[35, 36] Assuming here that no major changes occur in secondary structure in the 
constrained mimetics in the temperature range studied (all shift vs. temperature plots were 
linear), the ΔδNH/ΔT data support the hydrogen-bonded hairpin registers predicted in the 
design process. 
 1H and 13C chemical shift deviations from random coil values (Δδ=δobserved - δrandom) 
were examined to provide further evidence for regular secondary structure (see Supporting 
Information). Positive values for ΔδHα and ΔδCß are expected for strands in ß-hairpins and 
negative values for ΔδCα.
[37-40] For the ΔδHα values, these expectations were largely observed 
(See Supporting Information), although the values are larger for the C-terminal strand than 
for the N-terminal strand of the ß-hairpin. The ΔδCα values were mostly in the negative 
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range, and the ΔδCß values were mostly positive, as expected, for the strand regions of a ß-
hairpin. 
 The strongest evidence for ß-hairpin conformations comes from analyses of NOEs. 
Key long-range NOEs detected in NOESY plots are shown in Figure-3. Notable is the 
extensive network of long range NOEs, between backbone protons (CαH and NH) in cross-
strand residues at HB and NHB positions, as well as between the side chains of residues 
located on the same face of the hairpin, including backbone Hα-Hα NOEs between R306-
T319 and H308-F317, HN-HN NOEs between K305-T320, and HN-Hα NOEs between 
I307-T319 and I309-F317. In addition, long range NOEs are seen between R306-F317, I307-
Y318, Y309-Y318, F317-T319 and Y318 and T320.  
 In summary, the NMR data provide strong support for a stable ß-hairpin conformation 
in the mimetic. Average solution structures were calculated using NOE-derived distance 
constraints (results are shown in Table-1). The solution NMR structures all possess a ß-
hairpin, and superimpose with a backbone rmsd of 1.01 Å. The tip region appears to be more 
flexible, adopting both type-I and type-II ß-turns (Figure-4). A comparison between the NMR 
structures for the mimetic and the antibody-bound V3 loop-derived peptide in crystal 
structure 2QSC, reveal excellent conformational mimicry of the antibody-bound peptide 
conformation (Figure-4). 
 
Antigenicity studies 
We found no published data on the affinity of the linear V3 peptide (called RP142) for the 
mAb F425-B4e8.[27, 31] However, a small amount of the F425-B4e8 antibody was available 
through the NIH AIDS Research and Reference Reagent Program, which was sufficient here 
for competition ELISA-based affinity comparisons. 
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 For competition ELISA, biotinylated-RP142 was immobilized on microtitre plates 
coated with streptavidin (see Supporting Information). Plates were incubated with a fixed 
concentration of mAb F425-B4e8 and increasing concentrations of competing peptide 
(RP142 or ß-hairpin mimetic). In this way, IC50 values were determined for the competing 
linear peptide (IC50 = 3.4 nM) and the ß-hairpin mimetic (IC50 = 0.8 nM). The results show 
that the mimetic binds to the mAb with high affinity. 
 
Immunogenicity studies 
We asked whether the mimetic can elicit a humoral immune response that cross-reacts with 
gp120 and with envelope spikes on native virions. The mimetic was coupled to a lipopeptide 
carrier (3)[16] that can self-assemble into SVLPs (Figure-5).[14, 15] To conjugate the mimetic to 
the lipopeptide carrier, a hydrazine group was added to the L-Pro residue of the template, as 
shown by peptide 1 in Figure-5. After synthesis of the new cyclic mimetic (1), the hydrazino 
group could be reacted selectively with 4-maleimidobutyryl-N-hydroxysuccinimide ester to 
give 2. The maleimido-labelled mimetic (2) was then coupled in high yield to the Cys residue 
in lipopeptide 3,[16] to give 4 (Figure-5) (see Supporting Information). When dissolved in 
phosphate-buffered saline (PBS), this lipopeptide (4) assembles spontaneously into SVLPs 
with a mean hydrodynamic radius by dynamic light scattering of ca. 20-25 nm (see 
Supporting Information). Based on earlier precedence, about 60-80 copies of the mimetic 
should be displayed over the surface of each nanoparticle, as illustrated in Figure-5B.[15, 16] 
 SVLPs obtained from lipopeptide 4 were used to immunize three New Zealand white 
rabbits, each three times. Sera were collected after each immunization. After the third 
immunization, IgG end-point titres against the lipopeptide 4 were shown by ELISA to be in 
the range 20-30'000. Serum from the highest responding rabbit showed an end-point titre of 
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23'000 also against the mimetic (1) coupled to biotin (see Experimental section), and this 
anti-serum was used for for further study. 
 The ability of the elicited polyclonal IgG to bind to recombinant gp120 was assayed 
by ELISA and by surface plasmon resonance (SPR, BIAcore) biosensor. First, the IgG 
fraction in serum from the highest responding rabbit was isolated by protein-G affinity 
chromatography. IgG binding to recombinant gp120 was then detected by ELISA, and the 
binding could be competed away in the presence of mimetic (Figure-6A). Binding studies 
were also performed by immobilizing recombinant gp120 from either strain JR-FL or from 
strain LAI, on a CM5 sensor chip by random amine coupling. The LAI strain was used as a 
control, since the anti-mimetic antibodies are not expected to bind to gp120 from this strain, 
since the V3 loop in this strain has a two-residue (QR) insertion at the tip of the loop as well 
as several mutations in the flanking ß-strands (see Figure-1). As expected, the sensorgrams 
revealed a strong interaction between the anti-mimetic IgG and immobilized gp120JR-FL, but 
not gp120LAI (see Supporting information). We conclude, therefore, that antibodies raised 
against the mimetic are able to recognize and bind recombinant gp120. 
 The neutralizing activity of the affinity-purified anti-mimetic IgG was tested using a 
luciferase reporter gene assay in TZM-bl cells, based upon single round infection with 
molecularly cloned Env-pseudotyped viruses.[41] The assays were performed with viruses 
pseudotyped with the envelopes of the neutralization sensitive, HIV-1 tier-1 strains MN and 
SF-162, and more neutralization resistant tier-2 viruses REJO and JR-FL, and the tier-3 virus 
10.14. In addition, mutant envelopes of these viruses with deleted V1V2 loop regions were 
probed.[42] As shown in Figure-6B, only infection by the neutralization-sensitive laboratory 
MN strain was successfully inhibited by the anti-mimetic antibodies. None of the 
neutralization-insensitive strains isolated from HIV-infected humans were inhibited, unless 
the V1V2 loop region was first deleted. All the V1V2 mutant viruses, except REJO were 
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highly sensitive to neutralization by the anti-mimetic antibodies. The neutralizing activity 
could also be competed-out by adding excess mimetic, consistent with neutralization being 
dependent upon anti-mimetic IgG (Figure-6C). As controls, no effects were observed upon 
infection by murine leukaemia virus envelope pseudotyped virus, and no inhibitory activity 
was seen for the pre-immune IgG fraction from the rabbits (not shown). 
 
Discussion 
Structural vaccinology is an emerging technology in vaccine development.[43] An increasing 
number of publications document the value of structural biology in defining the 3D structures 
of epitopes recognized by neutralizing antibodies on various pathogenic organisms. One way 
to exploit this structural information is to design synthetic peptidomimetics with defined 
conformations that can be used to elicit immune responses. However, a method is also 
needed to effectively target the mimetics to immune cells and elicit potent immune responses. 
In this work, we demonstrate one very effective method for generating mimetics of ß-hairpin 
epitopes, which can be rendered immunogenic by presentation on the surface of SVLPs. 
 The V3 loop of HIV-1 has been the focus of many earlier studies in vaccine design. 
Early structural studies focused on Fab fragments of mAbs generated against 
conformationally flexible linear and disulfide-bridged V3-derived peptides.[44-50] Early efforts 
to constrain such V3-derived peptides included the replacement of the Ala in the loop tip 
(Figure-1) by the α-aminoisobutyryl (Aib) residue,[51] and backbone macrocyclization using a 
hydrazone link as a mimic of a cross-strand hydrogen bond.[46, 52, 53] Macrocyclic V3 loop 
mimetics have also synthesized, coupled to outer membrane proteins of Neisseria 
meningitidis and used for immunizations.[54, 55] 
 More recently structures of several V3-derived peptides bound to the murine anti-
gp120 (HIV-1IIIB strain) mAb (called 0.5ß) and to the human mAb 447-52D, were determined 
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by NMR.[56-59] An HIV-1IIIB-derived peptide in complex with the 0.5ß mAb was shown to 
adopt a type-VI ß-turn at RGPG, with the central GP peptide bond in a cis conformation at 
the ß-hairpin tip. This information was used to design a cis-GP peptide bond mimetic 
stabilized by a pseudoproline derivative.[60] In another study, a trans-GP conformation was 
stabilized by a spirocyclic Freidinger-like lactam.[61] Several more recent studies have used 
single or double disulfide-bridges, as well as replacement of P313 by D-Pro, to stabilize and 
mimic ß-hairpin conformations in V3 loop peptides.[62-64] However, none of these approaches 
to hairpin mimetic design are as effective as the one reported here in stabilizing the antibody-
bound form of the antigen. This is demonstrated here by the very close structural similarity of 
the mimetic with that of a V3 peptide bound to F425-B4e8 (Figure-4). The use of a D-Pro-L-
Pro template to design macrocyclic hairpin mimetics is a straightforward and highly effective 
approach that should be widely useful in generating accurate structural mimetics of ß-hairpin 
motifs. We could also show that the mimetic binds to F425-B4e8 with high affinity. 
 We also tested whether the mimetic displayed on SVLPs (i.e. lipopeptide 4), is able to 
elicit F425-B4e8-like antibodies that can bind to gp120, and exhibit HIV-1 neutralising 
activity. The immunogen (lipopeptide 4) assembles into nanoparticles in aqueous buffers 
with a diameter of ca. 20-30 nm, which should display ca. 60-80 copies of the mimetic across 
the surface of the nanoparticle (Figure-5). The lipopeptide 4 also contains a promiscuous T 
helper epitope derived from the malaria parasite,[16] and SVLP formation is driven by the 
presence of a Pam3Cys moiety, which is a known Toll-Like Receptor (TLR) ligand.[13] These 
V3 mimetic-coated nanoparticles elicited antibodies in rabbits, without the use of an 
adjuvant, that indeed bind strongly to recombinant gp120 by ELISA (Figure-6). However, 
only infection by the neutralization-sensitive laboratory MN strain was successfully inhibited 
by the anti-mimetic IgG. None of the neutralization-insensitive strains isolated from HIV-
infected humans were inhibited, unless the V1V2 loop region was first deleted. All the V1V2 
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mutant viruses, except REJO were highly sensitive to neutralization by the anti-mimetic 
antibodies. 
 The V1V2 variable loop in gp120 exibits length and sequence polymorphism across 
diverse HIV-1 strains, but its deletion is tolerable and is known to yield replication competent 
viruses. Moreover, the V1V2 loop has a profound influence on the virus' susceptibility to 
neutralization, in particular, by shielding neutralizing epitopes in the V3 loop.[65-71] 
Unmasking of V1V2 reveals potent neutralizing activity by many monoclonal antibodies 
directed against the V3 loop. The results obtained here with the anti-mimetic antibodies are 
consistent with this effect, and provide potentially valuable information for future HIV-1 
vaccine design. The mechanism of shielding by V1/V2 is of great interest. A recent study 
concluded that V1V2 protects the V3 loop of a neighboring gp120 in the context of the native 
trimer in the spikes on the viral surface.[42] Hence, the quaternary structure of gp120 allows 
inter-subunit contacts that effectively shield cross-neutralization-sensitive epitopes. New 
strategies are now required to overcome this V1V2 shielding, in order to fully exploit the 
therapeutic potential of V3 loop cross-reactive antibodies, and V3 loop mimetics in vaccine 
design. 
 
 
 
Experimental Section 
Peptide synthesis 
All peptides were prepared using Fmoc-chemistry with methods described elsewhere.[14, 16, 33] 
Full details of synthetic procedures and characterization of products are given in the 
Supporting Information. 
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Conformational studies by NMR 
1H NMR measurements were performed in H2O/D2O (9:1) or pure D2O, at pH 5.0, at 1-3 mM 
peptide. Spectra were acquired for structure calculations on a Bruker AV-600 spectrometer at 
300 K. Data were processed using TOPSPIN 2.1 (Bruker) or XEASY.[72] Water suppression 
was performed by presaturation. Spectral assignments were made using 2D DQF-COSY, 
TOCSY and NOESY spectra. 3JHNα coupling constants were determined from 1D spectra or 
from 2D NOESY spectra by inverse Fourier transformation of in-phase multiplets.[73] 
 [13C,1H]-HSQC spectra at natural abundance were recorded in D2O. Acquisition data 
were sampled as 1024x512 complex points in t2 and t1. The 2D data matrices were multiplied 
by a square-sine-bell window function and zero-filled to 2x2k points prior to Fourier 
transformation. Distance restraints were obtained from NOESY spectra with a mixing time of 
250 ms. Spectra were typically collected with 1024 x 256 complex data points zero-filled 
prior to Fourier transformation to 2048 x 1024, and transformed with a cosine-bell weighting 
function. The structure calculations were performed by restrained molecular dynamics in 
torsion angle space using DYANA[74] and only NOE-derived distance restraints. Starting 
from 100 randomized conformations a bundle of 20 final structures were selected, which 
encur the lowest DYANA target energy function. The program MOLMOL[75] was used for 
structure analysis and visualization of the molecular models. DYANA structures were 
optimized by energy minimization using the program MOE (Chemical Computing Group, 
Canada). 
 
Competition ELISA with antibody F425-B4e8 
ELISA microtiter plates (Nunc Immunoplates Polysorb F96) were coated overnight with 
streptavidin (5 µg/mL) in carbonate buffer (50 µL, 0.2 M, pH 9.6). The wells were then 
washed with PBS (10 mM sodium phosphate, 154 mM NaCl, pH 7.2) containing 0.05% 
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Tween 20 (PBST) and blocked with PBS containing 4% BSA (100 µL) for 1 h. After 
blocking, the wells were washed three times with PBST and incubated with the peptide 
biotin-GGGGYNKRKRIHIGPGRAFYTTKNIIG (50 µL, 5 nM) in PBS for 1 h. After 
washing, antibody F425-B4e8 (40 pM) pre-incubated with a competing ligand in PBS for 2 h, 
was added for 1 h. After washing with PBST, the plates were incubated with horseradish 
peroxidase labeled goat anti-human IgG diluted 1:20’000 in PBST containing 0.1 % BSA 
(50 µL) for 1 h. Color was developed for 30 min using 3,3’-5,5’-tetramethylbenzidine 
dihydrochloride hydrate (50 µL, 0.3 mg/mL) in Buffer A (100 mM citric acid and 122 mM 
disodium hydrogen phosphate dihydrate, pH 4.0) containing 0.1 % H2O2. After adding a stop 
solution (50 µL, 2 M H2SO4), the absorbance was read at 450 nm using a SpectraMax M5 
microplate reader. All experiments were conducted in duplicate. Absorbance values were 
converted into % inhibition using the equation %-inhibition = (1 - (A/Ao)) x 100, where A 
represents the value in the presence of inhibitor and Ao is the value without inhibitor (see 
Supporting Information). The IC50 was calculated using the program IGOR Pro 6.01 
(WaveMetrix Inc.). 
 
Determination of anti-mimetic IgG endpoint titres 
Microtiter plates (Nunc Immunoplates Polysorb F96) were coated overnight with streptavidin 
(50 µL, 5 µg/mL) in PBS. The wells were then washed with PBS containing 0.05% Tween 20 
(PBST) and blocked with PBS containing 4% BSA (100 µL) for 1h. The wells were then 
washed three times with PBST and incubated with mimetic (1) coupled through a PEG linker 
to biotin (biotinyl-PEG-mimetic (6)) (for the synthesis of this ligand see Supporting 
Information) in PBS (50 µL, 1.5 µg/mL). After washing with PBST the plates were incubated 
with serial dilutions of rabbit sera (50 µL) in PBS containing 0.05% Tween 20 and 0.5 % 
skim milk powder (MPBST) for 2.5 h, followed by three washes with PBST. The plates were 
 16 
then incubated with alkaline phosphatase-conjugated mouse anti-rabbit IgG antibody (Sigma, 
γ-chain specific), diluted 1:20’000 in MPBST (50 µL) for 1 h, washed again three times with 
PBST and incubated in the dark with p-nitrophenyl phosphate (Sigma) (50 µL, 1 mg/mL) in  
sodium carbonate buffer (50 mM) containing MgCl2 (1mM, pH 9.6). The absorbance was 
measured at 405 nm using a SpectraMax M5 microplate reader. 
 
Binding of anti-mimetic IgG to gp120  
Gp120JRFL (Progenics) was diluted with coating buffer (0.05 M sodium carbonate, pH 9.6) to 
a final concentration of 2.5 µg/mL, and aliquots (50 µL) were used to coat wells of a 
microtiter plate (Maxisorp, Nunc) overnight at 4 ºC. After washing with PBST, wells were 
blocked with PBS containing 5% skim milk powder (100 µL per well) for 30 min. After 
washing, polyclonal IgG (50 µL, 10 µg/mL) isolated from rabbit serum was pre-incubated 
with serial dilutions of the competing peptide mimetic (50µL per well) in PBS for 1 h, and 
then dispensed into wells and incubated for 1 h. After washing, alkaline phosphatase-
conjugated mouse anti-rabbit IgG antibody (Sigma, γ-chain specific, diluted 1:20’000 in 
MPBST, 50 µL) was added to each well and incubated for 1 h. The plate was washed with 
PBST and then incubated in the dark with p-nitrophenyl phosphate (Sigma) (50 µL, 1 
mg/mL) in sodium carbonate (50 mM ) with  MgCl2 (1 mM, pH 9.6). The absorbance was 
measured at 405 nm using a SpectraMax M5 microplate reader. All experiments were 
conducted in duplicates. Error bars indicate standard deviations of duplicate determinations 
(Figure-6A). The data were analyzed using the program IGOR Pro 6.01 (WaveMetrix Inc.). 
 
Neutralization assays 
The origins of the HIV-1 strains, the generation of V1V2-deleted envelopes, and the 
neutralization assays with Env-pseudotyped virus were performed as described earlier.[42] 
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Table-1. Experimental distance restraints and statistics for the final 20 NMR structures 
(shown in Figure-4) calculated for the mimetic using DYANA.[74] 
 
 results 
NOE upper-distance 
limits: total 
  Intraresidue 
  Sequential 
  Medium-and longe   
  range 
 
144 
42 
62 
40 
Residual target function 
value (Å2) 
 
0.96 ± 0.05 
Mean rmsd value (Å) 
  All backbone atoms 
  All heavy atoms 
 
1.01 ± 0.50 
2.03 ± 0.63 
Residual NOE violations 
  Number > 0.2 Å 
  Maximum (Å) 
 
5 
0.28 
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Figures 
Figure-1. A, Crystal structures of engineered HIV-1 gp120 core (pink) (with V1V2 loop 
deleted) with an intact V3 (red), bound to CD4 (green) and an antibody Fab fragment (blue). 
Left, structure PDB 2B4C; right, structure PDB 2QA. B, V3 loop sequences from the viral 
strains shown with the location of base, stem and tip (crown) regions. The flanking Cys 
residues are linked by a disulfide bond in gp120. 
A 
 
B 
 
 
 
 
 
 
 
 
 
       base       stem                     tip                     stem              base 
     
strain              296             301            306              320               326   331 
                                                                                    
IIIb  CTRPNNNTRKKIRIQRGPGRAFVTIGK-IGNMRQAHC 
JR-FL CTRPNNNTRKSIHI--GPGRAFYTTGEIIGDIRQAHC 
MN  CTRPNYNKRKRIHI--GPGRAFYTTKNIIGTIRQAHC 
LAI  CTRPNNNTRKSIRIQRGPGRAFVTIGK-IGNMRQAHC 
F425-B4e8         RKRIHI--GPGRAFYTT    
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Figure-2. A, Ribbon representation of the crystal structure PDB 2QSC showing the V3 
peptide (green) bound to the antibody F425-B4e8. B, The antibody-bound V3 loop 
conformation with cross-strand hydrogen bonding (HB) shown by dotted lines, and selected 
ß-carbons shown as balls. The hairpin mimetic (right) is shown with dotted boxes to indicate 
cross-strand HB pairs. 
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Figure-3. Top, 3JHNHα (Hz) and -Δδ/T (ppb/K) values for the mimetic. Bottom, key cross-
strand NOE connectivities observed in 1H NMR 2D-NOESY plots for the mimetic. The 
observed NOEs are indicated by dotted arrows. 
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Figure-4. Top, Average solution NMR structures for the mimetic; (left) all structures 
backbone-superimposed; (middle) one typical structure (Ile, green; Phe, dark pink; Tyr, light 
pink; Pro, orange; Gly, yellow); (right) comparisons of NMR (blue) with the corresponding 
antibody-bound V3 loop structure (orange) (see text). Bottom, Superimposition of the NMR 
structure of mimetic (red) with the linear peptide (purple) bound to F425-B4e8 in crystal 
structure PDB 2QSC. 
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Figure-5. A, A hydrazino-derivative of mimetic 1 was coupled to lipopeptide 3, to give 4, 
which spontaneously assembles into 20-25 nm nanoparticles (SVLPs) in buffered solution. B, 
A computer model of the nanoparticle, with 72 copies of the loop mimetic (1) shown in red 
on the surface, and the coiled coil in blue/yellow. The lipid chains are buried in the core of 
the particle.[15, 16] 
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Figure-6. Immunogenicity of lipopeptide-mimetic (4). A, Inhibition of anti-4 IgG binding to 
immobilized gp120 by ELISA; binding is inhibited by increasing concentrations (in µM) of 
mimetic. B, Neutralizing activity of rabbit anti-4 IgG against molecularly cloned Env-
pseudotyped HIV-1 viruses, including wild-type (WT) envelope of strains MN, 10.14, 
SF162, JR-FL and REJO, and mutant envelopes with the V1V2 loop deleted (see text). C, 
Neutralizing activity of rabbit anti-4 IgG (tested at 25 and 50 µg/ml, from 2° immunization, 
rabbit A) was probed at the indicated concentrations for inhibitory activity against MN and 
10.14-ΔV1V2 in the presence and absence of competing mimetic (10 µM); showing that the 
neutralizing activity can be competed-out by free mimetic. 
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Graphic for Table of Contents 
 
A structural vaccinology approach may lead to a new generation of vaccine candidates, based 
upon conformationally constrained epitope mimetics. Here a ß-hairpin mimetic of the HIV-1 
V3 loop is rendered immunogenic by multivalent display on the surface of synthetic virus-
like particles (SVLPs). 
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1. Abbreviations 
2. Synthesis of the V3 hairpin mimetic 
3. Synthesis of hydrazino-mimetic (1) 
4. Synthesis of peptide 2 
5. Synthesis of lipopeptide 4 
6. Synthesis of biotinyl-PEG-mimetic (6) 
7. Competition ELISA with antibody F425-B4e8 
8. Immunization protocol 
9. IgG Isolation from rabbit serum 
10. Binding of anti-mimetic antibodies to gp120 by SPR (BIAcore) 
11. NMR Chemical shift deviations from random coil values  
 
 
1. Abbreviations 
Boc, t-butoxycarbonyl; DIEA, N,N-diiso-propylethylamine, DCM, dichloromethane, DMF, 
N,N-dimethylformamide; Fmoc, 9-fluorenylmethoxycarbonyl; HATU, 2-(1H-7-
azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; HBTU, 2-[1H-
benzotriazole-1-yl]-1,1,3,3-tetramethyluronium hexafluoro-phosphate; HOAt, 1-hydroxy-7-
azabenzotriazole; HOBt, 1-hydroxybenzotriazole; Pbf, 2,2,4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl; PyBOP, benzotriazole-1-yloxy-tris-pyrrolidino-
phosphonium hexafluorophosphate ; TIS, triisopropylsilane; TFA, trifluoroacetic acid; Trt, 
trityl. 
 
 32 
2. Synthesis of the V3 hairpin mimetic 
Peptide synthesis was initiated with Fmoc-D-Pro-OH pre-loaded on 2-chlorotrityl chloride 
resin on a 0.25 mmol scale. The protected amino acids used were Fmoc-Ala-OH, Fmoc-
Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-His(Trt)-OH, Fmoc-Ile-OH, Fmoc-Lys(Boc)-OH, 
Fmoc-Pro-OH, Fmoc-D-Pro-OH, Fmoc-Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Tyr(tBu)-OH. 
The synthetic method was described earlier.1 
 Peptides were purified by preparative RP-HPLC (Waters C18 XBridge 5 µm, 300 Å, 
19 x 50 mm) using a linear gradient of 10-40% MeCN in water with 0.1% TFA in 20 min at 
14 mL/min. HPLC fractions containing the desired product were pooled, frozen and 
lyophilized. Peptides were analyzed by MALDI-TOF MS and analytical RP-HPLC (Dr. 
Maisch ReproSil Gold C18, 5 µm, 4 x 250 mm or Agilent Zorbax Eclipse XDB-C18, 5 µm, 
4.6 x 250 mm) using a gradient of 10-60% MeCN in water with 0.1% TFA in 12 min at 
0.7 mL/min. tR = 6.99 min. MALDI-MS  m/z 1793.0 (calc. 1793.0). 
 
3. Synthesis of hydrazino-mimetic (1) 
The peptide Gly-Ile-His(Trt)-Ile-Arg(Pbf)-Lys(Boc) was assembled (0.2 mmol scale) using 
standard Fmoc chemistry on 2-chlorotrityl resin (Novabiochem, loading 0.7 mmol g-1) and 
HBTU/HOBt/DIPEA for activation. (2S,4R)-N-Benzyloxycarbonyl-4-(N’,N’N’-tri-tert-
butoxycarbonyl-hydrazino)proline (0.28 mmol, 0.19 g, 1.4 eq) was coupled manually to the 
resin bound peptide chain using HATU (0.3 mmol, 0.114 g, 1.5 eq) in DMF (5 mL) and 
DIEA (0.6 mmol, 100 µL, 2 eq), with shaking for 75 min at room temp, then the solution was 
filtered and the resin was washed with DMF (3x 5 mL) and DCM (3x 5 mL). Assembly of 
the peptide chain was then completed using standard Fmoc chemistry. The resin-bound 
peptide was treated seven times with a solution of 20 % piperidine in DMF (v/v) (5 mL). The 
resin was washed with DMF (5 x 5 mL) and DCM (4 x 5 mL) and dried over KOH pellets in 
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vacuo. The linear peptide was cleaved from the resin using 0.6 % TFA in DCM (10 x 5 mL, 
each 30 s). The filtrate was collected in a flask containing a solution of DIEA (200 µL) in 
DCM (5 mL). The solvent was evaporated in vacuo. The residue dissolved in DMF (30 mL) 
was treated with HOBt (0.31 mmol, 47.3 mg, 3 eq), PyBOP (0.30 mmol, 154.6 mg, 3 eq) and 
DIEA (0.87 mmol, 144 µL, 9 eq) was added under argon. After stirring overnight at room 
temp, DMF was removed in vacuo. The peptide was precipitated with cold water (50 mL) 
and collected by filtration. A solution of TFA:TIS:H2O (95 : 2.5 : 2.5 (v:v:v); 10 mL) was 
added. After stirring for 1.5 h at room temp, TFA was removed by evaporation in vacuo and 
the peptide was precipitated with ice-cold Et2O, washed with ice-cold Et2Oand then air-dried. 
The peptide was purified by preparative RP-HPLC on a C18 column (Waters XBridge C18, 
50x19 mm, 5 µm, 135 Å) using a gradient of 5 to 60 % MeCN in water (+ 0.05% formic acid) 
over 10 min at 14 mL/min (tR=3.62 min) to give a white powder. Yield: 8.8 mg. The peptide 
(>95%) was characterized by analytical RP-HPLC (Agilent Zorbax Eclipse XDB-C18, 5 µm, 
4.6 x 250 mm; gradient: 10 to 60 % MeCN in H2O containing 0.1 % TFA at 1 mL/min); 
tR = 9.63; ESI-MS m/z 1822.8 [M+H]+; 912.1 [M+2H]2+; 608.0 [M+3H]3+, MALDI-TOF 
1822.9 [M+H]+; m/z calculated for C84H132N27O19 1823.0 [M+H]+. 
 
4. Synthesis of peptide 2 
A solution of N-succinimidyl-4-maleimidobutyrate (Sigma) (1.0 mg, 3.6 µmol, 1.0 eq) in 
H2O/THF (1:1, 150 µL) was added to a solution of peptide 1 (6.6 mg, 3.6 µmol) in H2O 
(3 mL) and the pH was adjusted to 5.3 by adding 0.1 M NaOH. The reaction mixture was 
stirred for 1 h at room temp. The product was purified by semipreparative RP-HPLC 
(Interchim, Interchrom C4, 250 x 10 mm, 5 µm, 300 Å) using a gradient of 25 to 60% MeCN 
in H2O (+ 0.1% TFA) over 7 min. tR = 5.58 min (yield: 3.9 mg, 55 %). Analytical RP-HPLC 
(Interchim, Interchrom UP5WC4-25QS, 10 to 100% MeCN in H2O (+ 0.1% TFA) over 17 
 34 
min at 1 mL/min: purity > 98%. tR = 9.16 min. ESI-MS m/z 497.9 [M+4H]4+; 663.3 
[M+3H]3+; 994.8 [M+2H]2+; m/z calculated for C92H138N28O22 1988.1 [M+H] +. 
 
5. Synthesis of lipopeptide 4 
A solution of lipopeptide 3 (prepared as described earlier 2) (0.54 µmol, 3.8 mg) in 
H2O / MeCN (1:1, 1 mL) was added to a stirred solution of peptide peptide 2 (0.70 µmol, 
1.4 mg, 1.3 eq) in H2O/MeCN (1:1, 0.5 mL) and the pH was adjusted to 6.5 by adding 0.1 M 
NaOH. After stirring for 1.5 h at room temp, the solution was lyophilized and the crude 
product was dissolved in H2O/MeCN (1:1, 2 mL) containing 0.1 % TFA and purified by 
semipreparative RP-HPLC on a C4 column (Interchrom) using a gradient of 30 to 100 % 
MeCN in water (+0.1% TFA) over 21 min followed by a wash with 100 % MeCN over 4 min 
at 4.5 mL/min (tR = 23.21 min). Yield: 3.0 mg. Purity was > 95 % by analytical RP-HPLC on 
a C4 column (Interchrom) using a gradient of 30 to 100 % MeCN in water (+0.1% TFA) over 
14 min at 1 mL/min followed by a wash with 100 % MeCN over 4 min at 1 mL/min (tR = 
17.57 min). ESI-MS (positive mode) m/z 1504.9 [M+6H]6+; 1290.2 [M+7H]7+; 1128.9 
[M+8H]8+; 1003.7 [M+9H]9+; 903.0 [M+10H]10+; 820.9 [M+11H]11+, 752.6 [M+12H]12+, 
694.8 [M+13H]13+; m/z 9021.6 ± 0.03%; MALDI-TOF 9023.7 [M+H]+; m/z calculated for 
C420H721N102O108S3 9023.2 [M+H]+. 
 
 
Analytical RP-HPLC chromatogram of peptide 4 (Interchim Interchrom UP5WC4-25QS (C4, 250 x 4.6 mm, 
5 µm, 300 Å), gradient: 30 to 100 % MeCN in water (+0.1% TFA) over 14 min at 1 mL/min followed by a wash 
with 100 % MeCN over 4 min at 1 mL/min (tR = 17.57 min). 
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MALDI-MS of lipopeptide 4. 
 
When dissolved in PBS, lipopeptide 4 spontaneously forms nanoparticles, as detected by 
dynamic light scattering (DLS) and electron microscopy (see also ref.2). Representative mass-
weighted size-distribution of lipopeptide 4 measured by DLS at a concentration of 1 mg/mL 
in PBS is shown below. A mean hydrodynamic radius (Rh) of 14.8 nm was estimated for all 
species that contribute > 99 % to the total mass-weighted light-scattering intensity, whereas 
the main species formed particles with a mean Rh of 13.1 nm. 
                 
Also shown is a representative electron micrograph of SVLPs formed by lipopeptide 4 
(1 µM) measured in TBS buffer containing 90 mM NaCl at a magnification of 135000x. The 
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scale bar indicates 100 nm. Particles with a diameter of ~20-25 nm are observed, although 
some particle aggregates are also seen. 
 
6. Synthesis of biotinyl-PEG-mimetic (6) 
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To peptide 1 (3.2 mg, 1.8 µmol) in H2O (1 mL) (pH = 5.3) at 0oC was added a solution of 
MAL-PEO8-NHS (Interchim) (1.5 mg, 2.1 µmol, 1.2 eq) in THF (500 µL). After stirring for 
4 h at room temp. the solution was lyophilized. The product (5) was dissolved in 10% MeCN 
in H2O + 0.1 % TFA (5 mL) and purified by semipreparative HPLC (Zorbax Eclipse C18) 
using a gradient from 10 to 100 % MeCN in H2O + 0.1 % TFA in 14.5 min at 5 mL/min 
(tR = 6.04 min). Yield: 2.9 mg. Analytical RP-HPLC (Agilent Zorbax Eclipse XDB-C18, 
5 µm, 4.6 x 250 mm; gradient: 10 to 100 % MeCN in H2O containing 0.1 % TFA in 17 min 
at 1 mL/min) tR = 7.87; ESI-MS m/z 800.0 [M+3H]3+; 600.0 [M+4H]4+; m/z 2396.5±0.02%; 
m/z calculated for C110H174N29O31 2397.3 [M+H]+. 
 A solution of biotinyl-Cys-NH2 (0.32 mg) and the peptide 5 (1.6 mg) in MeCN/H2O 
was stirred for 1 h at pH 6 for coupling to occur. The product (6) was purified by analytical 
RP-HPLC (Agilent Zorbax Eclipse XDB-C18, 5 µm, 4.6 x 250 mm; gradient: 10 to 100 % 
MeCN in H2O containing 0.1 % TFA in 12 min at 1 mL/min; tR = 6.79). Yield: 1.8 mg. The 
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product was obtained in > 98 % purity as assessed by analytical HPLC analysis. ESI-MS m/z 
915.9 [M+3H]3+; 696.9 [M+4H]4+; MALDI-TOF m/z 2743.3 [M+H]+; m/z calculated for 
C123H196N33O34S2 2743.4 [M+H]+. 
 
7. Competition ELISA with antibody F425-B4e8 
The results shown below were used to determine IC50 values for the hairpin mimetic (solid 
line) and linear peptide (RP142) (dotted line): 
 
 
8. Immunization protocol 
Immunizations were performed with three New Zealand white rabbits. The lipopeptide 4 was 
dissolved in PBS and injected intramuscularly (no adjuvant was used) (150 µg of 4 in 400 µl 
PBS per immunization). Three immunizations were performed on days 1, 28 and 56, and 
serum was collected on days 0 (pre-immune serum), 14, 38 and 66. 
 
9. IgG Isolation from rabbit serum 
Rabbit serum was diluted 1:10 in equilibration buffer (50 mM Tris-HCl, 150 mM NaCl, pH 
8.6) and filtered through 0.2 µm filter units (Whatman). The diluted serum was loaded onto a 
pre-equilibrated HiTrapTM Protein G affinity column (GE Healthcare) with a flow rate of 
0.7 mL/min. After washing away unbound proteins, the bound IgG fraction was eluted with 
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elution buffer (50 mM glycine-HCl, pH 3.0) at a flow rate of 0.7 mL/min, and neutralized 
with neutralization buffer (500 mM sodium phosphate, pH 7.6). Neutralization was 
performed by collecting the IgG fractions into tubes containing 1/5 volume of neutralization 
buffer. Desalting of the antibody solution into PBS buffer was performed using a HiTrapTM 
desalting column (5 mL, GE Healthcare) at a flow rate of 5 mL/min. The antibody solution 
was then concentrated to a final concentration of 1-2 mg/mL using a centrifugal filter device 
(YM-50 Centricon, Millipore) and sterile filtered through 0.1 µm filter devices (Millipore). 
The concentration was determined based on the theoretical extinction coefficient of 
ε = 0.203 M-1cm-1 (OD = 1.35 for a 1 mg/mL IgG solution). The purity of polyclonal IgG 
fraction was confirmed by SDS-PAGE, showing bands of 25 kDa for light chains and 50 kDa 
for heavy chains detected under reducing conditions (4 x SDS buffer containing 12 % SDS, 
30 % glycerol, 20 % mercaptoethanol, 4 mM EDTA, 80 mM Tris). 
 
10. Binding of anti-mimetic antibodies to gp120 by SPR (BIAcore) 
Recombinant gp120 from strain JR-FL was immobilized on a CM5 sensor chip (BIAcore, GE 
Healthcare) by random amine coupling. The isolated IgG fraction from rabbit serum, 
following the third immunization, was eluted over the sensor using a BIAcore 3000 
instrument. The resulting sensorgrams are shown below. 
 The BIAcore sensograms show the response upon direct binding of polyclonal IgG to 
immobilized gp120JRFL on the CM5 chip surface. Polyclonal antibody concentrations from 
top to bottom are 2000 nM, 1000 nM, 500 nM, 250 nM, and 125 nM. The blank lines indicate 
the fit of recorded data to a 1:1 Langmuir binding model using the BIAevaluation software 
v.4.0.1. Note that this data cannot be used to determine binding constants, since the 
antibodies are bivalent and polyclonal. The results demonstrate the presence of antibodies in 
serum that are able to recognize and bind gp120JRFL. As a control, the experiment was 
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repeated using gp120 from HIV-1 strain LAI, but this gave no BIAcore response (data not 
shown), indicating that the antibodies are not able to recognize the gp120 from this strain. 
 
 
11. NMR Chemical shift deviations from random coil values 
Chemical shift deviations from random coil values (δobserved - δrandom) for Hα, Cα and Cß 
resonances for the mimetic were measured. The results are shown below. For strands in ß-
hairpins positive values for ΔδHα and ΔδCß and negative values for ΔδCα are expected.
3-6 
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